TY - JOUR
T1 - Management of sacrococcygeal chordoma
T2 - A systematic review and meta-analysis of observational studies
AU - Ahmed, Ahmed T.
AU - Abdel-Rahman, Omar
AU - Morsy, Mohamed
AU - Mustafa, Karim
AU - Testini, Paola
AU - Aleem, Ilyas S.
AU - Murad, Mohammad Hassan
AU - Nassr, Ahmad
N1 - Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Study Design. Systematic review and meta-analysis of observational studies. Objective. The aim of the study is to evaluate different treatment modalities in the management of sacrococcygeal chordoma. Summary of Background Data. Chordomas are primary malignant bone tumors associated with considerable morbidity and mortality. Methods. We searched MEDLINE, EMBASE, Cochrane Central- Register of Controlled Trials, and Scopus from inception to July 2015. Eligible studies included patients with sacrococcygeal chordoma treated exclusively with surgery, radiotherapy, or both. Two reviewers independently assessed the eligibility of potential studies, risk of bias, and extracted data. Outcomes of interest were all-cause mortality, progression-free survival, and metastases. We analyzed further surgical outcomes by resection margin. All outcomes were assessed at 60 months and more than 60 months following intervention. Results. We included 33 noncomparative studies reporting on 501 patients (mean age 57 years). Overall mortality rate was (16%) after surgical resection with adjuvant radiotherapy and (28%) after surgical resection, and (43%) after radiotherapy (P=0.28). All-cause mortality following wide surgical resection was (32%) compared to (40%) after marginal resection (P=0.51). Overall progression-free survival rate was (58%) after surgical resection with adjuvant radiotherapy and (55%) after surgery (P=0.92). However, at more than 60 months follow-up, progression- free survival rates were significantly higher (P=0.024) following surgical resection with adjuvant radiotherapy (74%) in comparison to surgery (55%) and radiotherapy (36%). Overall progression-free survival rates were nonsignificantly higher after wide surgical resection (66%) than marginal resection (33%) (P=0.16). However, at 60 months follow-up, progression-free survival rates were significantly higher following wide surgical resection (73%) than marginal resection (33%) (P=0.047). Conclusion. Sacrococcygeal chordoma is a difficult to treat disease entity. Until comparative studies become available, wide surgical resection and multidisciplinary management are the recommended approaches to improve patient outcomes.
AB - Study Design. Systematic review and meta-analysis of observational studies. Objective. The aim of the study is to evaluate different treatment modalities in the management of sacrococcygeal chordoma. Summary of Background Data. Chordomas are primary malignant bone tumors associated with considerable morbidity and mortality. Methods. We searched MEDLINE, EMBASE, Cochrane Central- Register of Controlled Trials, and Scopus from inception to July 2015. Eligible studies included patients with sacrococcygeal chordoma treated exclusively with surgery, radiotherapy, or both. Two reviewers independently assessed the eligibility of potential studies, risk of bias, and extracted data. Outcomes of interest were all-cause mortality, progression-free survival, and metastases. We analyzed further surgical outcomes by resection margin. All outcomes were assessed at 60 months and more than 60 months following intervention. Results. We included 33 noncomparative studies reporting on 501 patients (mean age 57 years). Overall mortality rate was (16%) after surgical resection with adjuvant radiotherapy and (28%) after surgical resection, and (43%) after radiotherapy (P=0.28). All-cause mortality following wide surgical resection was (32%) compared to (40%) after marginal resection (P=0.51). Overall progression-free survival rate was (58%) after surgical resection with adjuvant radiotherapy and (55%) after surgery (P=0.92). However, at more than 60 months follow-up, progression- free survival rates were significantly higher (P=0.024) following surgical resection with adjuvant radiotherapy (74%) in comparison to surgery (55%) and radiotherapy (36%). Overall progression-free survival rates were nonsignificantly higher after wide surgical resection (66%) than marginal resection (33%) (P=0.16). However, at 60 months follow-up, progression-free survival rates were significantly higher following wide surgical resection (73%) than marginal resection (33%) (P=0.047). Conclusion. Sacrococcygeal chordoma is a difficult to treat disease entity. Until comparative studies become available, wide surgical resection and multidisciplinary management are the recommended approaches to improve patient outcomes.
KW - Meta-analysis
KW - Mortality
KW - Progression-free survival
KW - Radiotherapy
KW - Sacrococcygeal
KW - Spinal chordoma
KW - Surgery
KW - Systematic review
KW - Wide resection
UR - http://www.scopus.com/inward/record.url?scp=85055194828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055194828&partnerID=8YFLogxK
U2 - 10.1097/BRS.0000000000002638
DO - 10.1097/BRS.0000000000002638
M3 - Review article
C2 - 29538244
AN - SCOPUS:85055194828
SN - 0362-2436
VL - 43
SP - E1157-E1169
JO - Spine
JF - Spine
IS - 19
ER -